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Summary
Germline NF1, c-RET, SDH, and VHL mutations cause familial pheochromocytoma. Pheochromocytomas derive from sym-
pathetic neuronal precursor cells. Many of these cells undergo c-Jun-dependent apoptosis during normal development
as NGF becomes limiting. NF1 encodes a GAP for the NGF receptor TrkA, and NF1 mutations promote survival after NGF
withdrawal. We found that pheochromocytoma-associated c-RET and VHLmutations lead to increased JunB, which blunts
neuronal apoptosis after NGF withdrawal. We also found that the prolyl hydroxylase EglN3 acts downstream of c-Jun and
is specifically required among the three EglN family members for apoptosis in this setting. Moreover, EglN3 proapoptotic
activity requires SDH activity because EglN3 is feedback inhibited by succinate. These studies suggest that failure of
developmental apoptosis plays a role in pheochromocytoma pathogenesis.S I G N I F I C A N C E
Pheochromocytomas originate from neural crest cells that also form the sympathetic nervous system. Most of these cells normally
die during development as growth factors such as NGF become limiting. Familial pheochromocytoma is genetically heterogeneous
because it can be caused by NF1, c-RET, SDH, or VHL germline mutations. Mutations in these genes are rare in sporadic pheochro-
mocytomas, however, unlike the usual Knudson two-hit scenario. Our findings explain these observations by linking the products of
these genes to the induction of apoptosis following NGF withdrawal in assays thought to mirror developmental culling of neuronal
progenitor cells. We also show that EglN3 prolyl hydroxylase activity is necessary for neuronal apoptosis in this setting and mecha-
nistically link this activity to the mitochondrial enzyme SDH.Introduction
Pheochromocytomas are adrenal medullary tumors that are
comprised of chromaffin cells, which are derived from sympa-
thetic neuronal progenitor cells. Germline mutations in either
NF1, c-RET, succinate dehydrogenase subunit genes (SDHB,
SDHC, SDHD), or von Hippel-Lindau (VHL) are the most fre-
quent cause of familial pheochromocytoma and are also com-
mon in seemingly sporadic pheochromocytoma (Maher and
Eng, 2002; Neumann et al., 2002). In contrast, somatic muta-
tions of these genes are rare in nonhereditary pheochromo-
cytomas (Maher and Eng, 2002), raising the possibility that
their functions must be altered during early development for
pheochromocytomas to ensue.
Inheriting a defective VHL allele causes VHL disease, which
is associated with an increased risk of hemangioblastomas,CANCER CELL : AUGUST 2005 · VOL. 8 · COPYRIGHT © 2005 ELSEVIER INclear cell renal carcinomas, in addition to pheochromocytomas
(Kaelin, 2002; Maher and Kaelin, 1997). Tumor development in
this setting requires somatic loss of the remaining wild-type
VHL allele in a susceptible cell. The VHL gene product, pVHL,
is the substrate recognition unit of an E3 ubiquitin ligase com-
plex that targets the α subunits of the heterodimeric transcrip-
tion factor HIF (hypoxia-inducible factor) for proteasomal deg-
radation (Kaelin, 2002; Schofield and Ratcliffe, 2004), and HIF
appears to play a causal role in hemangioblastoma and clear
cell renal carcinoma (Kim and Kaelin, 2004; Kondo et al., 2003;
Zimmer et al., 2004). A number of other functions have been
attributed to pVHL, but their relevance to pVHL-defective tu-
mor formation is unclear (Czyzyk-Krzeska and Meller, 2004;
Kaelin, 2002).
Several lines of evidence suggest that the role of pVHL in
pheochromocytoma is qualitatively different from its role inC. DOI 10.1016/j.ccr.2005.06.015 155
A R T I C L Ehemangioblastoma and renal carcinoma. First, biallelic VHL in-
activation is common in sporadic hemangioblastoma and renal
carcinomas but rare in sporadic pheochromocytomas (absent
an occult germline VHL mutation), in violation of the Knudson
two-hit model, wherein mutation of the same tumor suppressor
gene is responsible for a hereditary cancer and its sporadic
counterpart (the first mutation or “hit” of the two having oc-
curred in the germline in hereditary cases) (Kim and Kaelin,
2004). This suggests that pheochromocytoma development in
VHL disease is due to a VHL+/− field defect or reflects the loss
of a critical pVHL function during development. Second, VHL
disease can be subclassified based on the risk of pheochromo-
cytoma (Zbar et al., 1996). Almost all VHL mutations linked to a
high risk of pheochromocytoma (type 2 disease) are missense
mutations, whereas null VHL mutations produce a low risk of
pheochromocytoma (type 1 disease) (Zbar et al., 1996). This
suggests that a mutant pVHL gain of function causes pheo-
chromocytoma or that complete (rather than partial) loss of
pVHL function is incompatible with pheochromocytoma de-
velopment. Finally, some VHL families display a high risk of
pheochromocytoma and a low risk of hemangioblastoma and
renal cell carcinoma (type 2C disease). Type 2C pVHL mutants
such as pVHL L188V appear to be normal with respect to HIF
regulation (Clifford et al., 2001; Hoffman et al., 2001), suggest-
ing that a pVHL target other than HIF is responsible for VHL-
associated pheochromocytomas.
Hydroxylation of specific prolyl residues within the HIF-α
subunits by EglN (also called PHD or HPH) triggers their rec-
ognition by pVHL (Kaelin, 2002; Schofield and Ratcliffe, 2004).
EglN1 is the primary HIF-α hydroxylase under normal condi-
tions in the many cell types examined to date, although all
three EglN family members (EglN1, EglN2, and EglN3) can hy-
droxylate HIF-α in vitro (Berra et al., 2003; A. Bommi-Reddy
and W.G. Kaelin, unpublished data; Bruick and McKnight,
2001; Epstein et al., 2001; Ivan et al., 2002). HIF dysregulation
could, in theory, be the unifying feature of VHL and SDH muta-
tions, since SDH inactivation would predictably attenuate prolyl
hydroxylation in cells for the reasons outlined below (see Re-
sults). As described above, however, some pheochromocy-
toma-associated pVHL mutants appear to be normal with re-
spect to HIF regulation (Clifford et al., 2001; Hoffman et al., 2001),
implying that HIF-independent pVHL functions are linked to
these tumors.
During embryogenesis, most sympathetic neuronal precur-
sor cells undergo c-Jun-dependent apoptosis as growth fac-
tors such as nerve growth factor (NGF) become limiting (Estus
et al., 1994; Ham et al., 1995; Schlingensiepen et al., 1994; Xia
et al., 1995). Disease-associated NF1 and c-RET mutations are
known or suspected to enhance signaling by NGF receptors
and promote neuronal survival (Dechant, 2002; Vogel et al.,
1995). Here, we report that pVHL mutants linked to pheochro-
mocytoma, including type 2C mutants, fail to downregulate the
c-Jun antagonist JunB, which also promotes survival after NGF
withdrawal. Moreover, the EglN1 paralog EglN3 (also called
PHD3, HPH1, SM-20) is induced in sympathetic neurons after
NGF withdrawal and provokes apoptosis when overexpressed
in pheochromocytoma cells (Lipscomb et al., 1999, 2001;
Straub et al., 2003). Based on these observations, we asked
whether EglN3 might link SDH to neuronal survival under NGF
limiting conditions. We found that EglN3, but not EglN1, is suf-
ficient to induce neuronal apoptosis and does so in a hydrox-156ylase-dependent manner. EglN3 acts downstream of c-Jun and
is necessary for apoptosis after NGF withdrawal. SDH inactiva-
tion blocks neuronal apoptosis induced by EglN3 overproduc-
tion or NGF withdrawal. Therefore, all of the known familial
pheochromocytoma genes affect a common pathway that culls
sympathetic neuronal precursors during development.
Results
pVHL downregulates JunB
We recently discovered that mRNA levels for the secreted pro-
tein clusterin are attenuated in VHL−/− renal carcinoma cells
(E. Nakamura et al., submitted). Notably, clusterin does not be-
have like a HIF target, and type 2C pVHL mutants, in contrast
to wild-type pVHL, do not restore clusterin expression when
reintroduced into such cells (E. Nakamura et al., submitted).
The clusterin promoter contains binding sites for Myb, AP-1,
and Sp1 (Cervellera et al., 2000; Herault et al., 1992; Jin and
Howe, 1997). In pilot experiments, we found that wild-type, but
not mutant, pVHL activated luciferase reporter plasmids con-
taining the clusterin promoter unless the AP-1 site was de-
stroyed (data not shown). This led us to examine the status of
specific AP-1 family members in cells that do or do not contain
wild-type pVHL. In electrophoretic mobility shift assays (EMSA),
we detected increased AP-1 activity (Figure 1A; Figure S1 in
the Supplemental Data available with this article online), due at
least partly to JunB (Figure 1B), in renal carcinoma cells lacking
wild-type pVHL. This effect was specific to JunB because the
AP-1 family members c-Jun and c-Fos were not affected by
pVHL in these assays (data not shown). JunB protein levels
were also elevated in HeLa cervical carcinoma cells after elimi-
nation of pVHL with three independent siRNAs (Figure 1C and
data not shown).
Regulation of JunB by pVHL involves both atypical
protein kinase C and HIF
786-O VHL−/− cells produce HIF-2α but not HIF-1α (Maxwell
et al., 1999). Type 2C pVHL mutants normalized HIF-2α levels
when reintroduced into 786-O cells (Clifford et al., 2001; Hoff-
man et al., 2001) (see also Figures 2C and 7E) but did not nor-
malize JunB levels (Figures 1D and 1E). Similarly, downregula-
tion of HIF-2α in 786-O cells with short hairpin RNAs (shRNA)
had little or no effect on JunB levels, in contrast to canonical
HIF targets such as GLUT1 (Figure 2A). On the other hand,
JunB was induced in cells containing wild-type pVHL that were
engineered to produce a stabilized form of HIF-2α or treated
with the hypoxia mimetic deferoxamine (DFO) (Figure 2B). Col-
lectively, these results suggested that either JunB is already
maximally stimulated at the residual HIF levels achieved with
type 2C mutants or HIF-2α shRNA, or that regulation of JunB
by pVHL involves HIF-dependent and HIF-independent path-
ways. The former possibility seems unlikely because JunB was
not induced by DFO in cells producing the type 2C pVHL mu-
tant L188V but was induced in cells producing wild-type pVHL,
even though these cells produced nearly identical levels of HIF-
2α and GLUT1 (Figure 2C).
The increased JunB protein levels observed in pVHL-defec-
tive cells, including those producing type 2C mutants, was as-
sociated with an w2– to 3-fold increase in JunB mRNA levels
(Figure S2). Transcription of JunB is regulated by atypical pro-
tein kinase C (PKC) family members (aPKC) (Kieser et al.,
1996), and pVHL has been reported to polyubiquitinate aPKCCANCER CELL : AUGUST 2005
A R T I C L EFigure 1. Increased JunB activity in pVHL-
defective cells
A: Electrophoretic mobility shift assay (EMSA)
with 32P-labeled DNA probes spanning Sp1 and
AP-1 sites in clusterin promoter and nuclear ex-
tracts prepared from 786-O VHL−/− renal carci-
noma cells transfected to produce wild-type
pVHL (WT8) or with empty vector (pRC3). WT,
wild-type probe; Sp1, Sp1 site-mutated probe;
AP-1, AP-1 site-mutated probe. Where indi-
cated, unlabeled DNA containing a canonical
Sp1 or AP-1 binding site was added as a com-
petitor (COMP). Arrowhead, AP-1 complex. B
and D: EMSA with 32P-labeled AP-1 site probe
and nuclear extracts prepared from indicated
cell lines. Anti-JunB antibody was added where
indicated. Arrow, supershift complex. WTD10
and pRCB3 are A498 VHL−/− renal carcinoma
cells transfected to produce wild-type pVHL or
with empty vector, respectively. D includes 786-O
cells transfected to produce pVHL R64P, L119S,
or L188V. C: Immunoblot analysis of HeLa VHL+/+
cervical carcinoma cells transfected with siRNA
against VHL or scrambled siRNA. E: Immunoblot
analysis of nuclear extracts used in D. Asterisk
indicates nonspecific band.(Okuda et al., 2001). In this earlier report, however, aPKC pro-
tein levels were not increased in pVHL-defective cells, leading
the authors to speculate that pVHL targets a minor subpopula-
tion of aPKC corresponding to the hyperphosphorylated, acti-
vated form of the enzyme. In support of this idea, we detected
an increase in a slowly migrating form of aPKC in immunoblot
assays of pVHL-defective cells (Figure 2D). This aPKC species
is likely to be a phosphorylated, and hence presumably acti-
vated, form of aPKC because a single, faster migrating aPKC
band was detected after treatment with lambda phosphatase
(data not shown). Importantly, this slowly migrating aPKC spe-
cies was suppressed by wild-type pVHL, but not type 2C pVHL
mutants, and its abundance was mirrored by changes in aPKC
kinase activity (Figure 2E). JunB, in contrast to HIF-2α and the
AP-1 family member c-Jun, was also downregulated with a
pharmacological aPKC inhibitor (Figure 2F and Figure S3).
These results suggest that pVHL regulates JunB via both aPKC
and HIF.
Loss of pVHL promotes neuronal survival
Pheochromocytoma cells are derived from sympathetic neu-
ronal precursor cells, and PC12 rat pheochromocytoma cells,CANCER CELL : AUGUST 2005which are VHL+/+, have been used as a model to study the
regulation of neuronal survival by NGF. During normal neuronal
development, many cells undergo apoptosis as they compete
for NGF. Loss of NGF leads to activation of c-Jun and the in-
duction of apoptosis (Ham et al., 1995; Palmada et al., 2002;
Schlingensiepen et al., 1994; Xia et al., 1995). PC12 cells re-
semble differentiated sympathetic neurons when grown under
low-serum conditions in the presence of NGF (Greene, 1978;
Greene and Tischler, 1976) (Figure 3A). The nuclei of PC12 cells
transfected to produce GFP-histone and induced to differenti-
ate with NGF were uniform and intact. Consistent with earlier
studies, NGF withdrawal led to morphological changes charac-
teristic of apoptosis, including plasma membrane blebbing,
cell body shrinkage, neurite retraction, and nuclear condensa-
tion and fragmentation (Deckwerth and Johnson, 1993; Ed-
wards and Tolkovsky, 1994) (Figures 3A and 3B). The percen-
tage of apoptotic cells at any time point is <20% with this
experimental paradigm because PC12 cells do not die syn-
chronously under these conditions (Francois et al., 2001; Mes-
sam and Pittman, 1998).
In addition to cell death, we observed that JunB is downreg-
ulated after NGF withdrawal from PC12 cells (Figure 3C). Since157
A R T I C L EFigure 2. Regulation of JunB by pVHL involves
HIF-dependent and HIF-independent pathways
A: Immunoblot analysis of 786-O VHL−/− renal
carcinoma cells retrovirally infected to produce
the indicated short hairpin RNAs (shRNA) or wild-
type pVHL (VHL).
B: Immunoblot analysis of RC3 cells and WT7
cells. Where indicated, WT7 cells were treated
with DFO or infected to produce HIF-2α
P405A;P531A or with empty retrovirus.
C: Immunoblot analysis of indicated 786-O sub-
clones grown in presence or absence of DFO.
Asterisk indicates nonspecific band.
D: Immunoblot analysis of A498 and 786-O cells
transfected to produce the indicated HA-pVHL
variants or with empty vector. Arrow indicates a
slowly migrating form of aPKC.
E: In vitro aPKC activity. Anti-aPKC immunopre-
cipitates of the indicated cell lines under anti-
body excess conditions were incubated with a
peptidic aPKC substrate in the presence of 32P-
γ-ATP. Shown are incorporated 32P values. Error
bars = 1 standard deviation.
F: Immunoblot analysis of 786-O cells treated
with the PKC inhibitor GF109230X.JunB antagonizes c-Jun in many settings, we asked whether
loss of pVHL or elevated JunB could block apoptosis after
NGF withdrawal. In these experiments, PC12 cells were again
transfected with a plasmid encoding GFP-histone to identify
transfected cells and score apoptotic nuclei, in addition to the
plasmid or siRNA of interest. After recovery from transfection,
the cells were grown in the presence of NGF for 5–7 days and
then placed in NGF-free media. Apoptosis was substantially
reduced by JunB (Figure 4A and Figure S4). This effect was
specific because it was not observed with a dimerization-
defective JunB mutant. Likewise, JunB suppressed apoptosis
of rat primary sympathetic neurons after NGF deprivation (Fig-
ure 4C). Treatment of PC12 with siRNA against rat VHL, but not
various control siRNAs, also decreased apoptosis after NGF
withdrawal (Figure 4B). This effect was specifically due to
downregulation of pVHL because it was reversed by a plasmid
encoding wild-type human pVHL. Importantly, the best-studied
type 2C pVHL mutant, L188V, did not reverse the effects of the158VHL siRNA (Figure 4B) despite its ability to downregulate HIF
(Figure 2C). In contrast, the elongin binding mutant pVHL
C162F, which is grossly defective with respect to HIF regulation
(Ohh et al., 2000) (see also Figure 7E), was partially active in
this assay. Collectively, these results implicate deregulation
of JunB and escape from NGF-dependent apoptosis in the
pathogenesis of VHL-associated pheochromocytoma. Simi-
larly, an activated c-RET mutant linked to pheochromocytoma
(C634R) and known to promote cell survival (De Vita et al.,
2000), but not wild-type c-RET, induced JunB in PC12 cells
and decreased apoptosis under NGF-poor conditions (Figures
4D and 4E).
Induction of neuronal apoptosis is a specific attribute
of EglN3 and is hydroxylase dependent
We confirmed the earlier observations of others that EglN3,
which in rat cells is called SM-20, is rapidly induced in PC12CANCER CELL : AUGUST 2005
A R T I C L EFigure 3. Apoptosis and increased JunB after NGF withdrawal
A and B: Phase-contrast and fluorescent photomicrographs of PC12 cells transfected to produce GFP-histone and grown in serum-rich media (undifferenti-
ated) or serum-poor media supplemented with NGF for 10 days, which was then withdrawn for 24 hr. White arrows indicate apoptotic nuclei, which were
quantitated in B as percentage of GFP-positive nuclei. Error bars = 1 standard deviation.
C: Immunoblot analysis of PC12 grown under serum-rich conditions (Undiff), under serum-poor conditions supplemented with NGF for 12 days, or after
NGF withdrawal.cells after NGF withdrawal and kills these cells when ectopi-
cally expressed (Lipscomb et al., 1999, 2001; Straub et al.,
2003) (Figure 5A and data not shown). We next transfected
undifferentiated PC12 cells with plasmids encoding hemagglu-
tinin (HA)-tagged versions of EglN1, EglN2, or EglN3 along with
the plasmid encoding GFP-histone. The nuclei of cells produc-
ing HA-EglN1 or HA-EglN2 appeared healthy 72 hr after trans-
fection and were comparable to cells producing GFP-histone
alone (Figures 5B and 5C). In contrast, the nuclei of 14%–20%
of the cells producing HA-EglN3 displayed the hallmarks of
apoptosis 48–72 hr after transfection. The fact that <20% of
the cells appeared apoptotic at any point in time is reminiscent
of the asynchronous cell death observed after NGF withdrawal
(Francois et al., 2001; Messam and Pittman, 1998). Increased
apoptosis was not observed in cells producing an EglN3 vari-
ant in which a canonical histidine residue important for hy-
droxylase activity was converted to alanine (H196A) (Figures
5B and 5C and Figure S5). Comparable amounts of the dif-
ferent EglN species were produced in these experiments as
determined by anti-HA immunoblot analysis (Figure 5D). There-
fore, induction of neuronal apoptosis is specific to EglN3
among the EglN family members and requires its enzymatic
activity. C. elegans have a single EglN gene called Egl-9 (Ep-
stein et al., 2001; Taylor, 2001). A role for EglN in neuronal apo-
ptosis is supported by the observation that Egl-9−/− worms are
resistant to certain neurotoxins (Darby et al., 1999).
EglN1, and not EglN3, appears to be the primary HIF prolyl
hydroxylase under normal conditions in cells (Berra et al., 2003;
A. Bommi-Reddy and W.G. Kaelin, unpublished data). More-
over, EglN3-induced apoptosis was not diminished when PC12
cells were cotransfected to produce HIF-1α or HIF-2α variants
that can not be hydroxylated on proline (Figure S6). Collec-
tively, these results suggest that HIF-α is not the relevant target
of EglN3 in this system.
Transfection of PC12 cells with SM-20 siRNAs, but not vari-
ous irrelevant or scrambled siRNAs, prior to differentiation and
NGF withdrawal substantially decreased apoptosis (Figures 5E
and 5F and Figure S7), indicating that EglN3/SM-20 hydrox-CANCER CELL : AUGUST 2005ylase is necessary, as well as sufficient, for the induction of
apoptosis by NGF withdrawal. Accordingly, apoptosis after
NGF withdrawal was also decreased under low-oxygen condi-
tions or in the presence of cobalt chloride, both of which inhibit
hydroxylase activity (Figures 5G and 5H).
SDH activity is required for EglN3/SM-20-induced
neuronal apoptosis
Prolyl hydroxylation by EglN family members, which belong to
a superfamily of 2-oxoglutarate (2-OG)-dependent dioxygen-
ases, is coupled to conversion of 2-OG into succinate (Aravind
and Koonin, 2001; Gunzler and Weidmann, 1998; Schofield
and Zhang, 1999). SDH is an inner mitochondrial membrane
enzyme that oxidizes succinate into fumarate as part of the
Krebs cycle and also participates in electron transport. Two
predictable outcomes of SDH inactivation would be the accu-
mulation of succinate, which feedback inhibits 2-OG-depen-
dent dioxygenases such as collagen prolyl hydroxylase and
thymine-7-hydroxylase in vitro (Holme, 1975; Myllyla et al.,
1977), and increased production of reactive oxygen species
(Lenaz et al., 2004; McLennan and Degli Esposti, 2000; Yan-
kovskaya et al., 2003), which can inhibit EglN activity (Gerald
et al., 2004). To test whether succinate can also inhibit EglN3
prolyl hydroxylase activity, we exploited the fact that EglN3 can
hydroxylate a HIF-1α-derived peptide in vitro, as determined
by capture of 35S-labeled pVHL (Bruick and McKnight, 2001;
Epstein et al., 2001). As predicted, EglN3 hydroxylase activity
was diminished in the face of increasing amounts of succinate
(Figure 6A). Hydroxylation activity was restored, however, by
the addition of 2-OG (Figure 6A), indicating that succinate and
2-OG act competitively in vitro. Intracellular succinate levels
can approach 0.5 mM and are in vast excess of 2-OG following
SDH inhibition (Selak et al., 2005). In addition, we confirmed
that ROS production was increased in PC12 cells treated with
pharmacological SDH inhibitors (Figure 6B), consistent with
findings obtained with cells expressing a mutated form of
SDHC (Ishii et al., 2005).
Motivated by these findings, we asked whether SDH activity159
A R T I C L EFigure 4. JunB blunts apoptosis after NGF with-
drawal
A and E: PC12 cells were transfected with a
plasmid encoding GFP-histone along with plas-
mid encoding wild-type JunB, dimerization-defec-
tive JunB (bZip), c-RET, or the backbone plas-
mid (Empty). Shown is the percentage of
GFP-positive nuclei exhibiting apoptotic changes
after growth in NGF for 5–7 days followed by
NGF withdrawal (−). Control, cells transfected
with GFP-His alone and maintained in NGF (+).
B: PC12 cells were transfected with a plasmid
encoding GFP-histone along with siRNA against
rat VHL (rVHL) and a plasmid encoding the indi-
cated human pVHL variants. Where indicated,
rVHL siRNA was replaced with scrambled (SC)
or luciferase (GL3) siRNA. Shown is the percen-
tage of GFP-positive nuclei exhibiting apoptotic
changes after growth in NGF for 5–7 days fol-
lowed by NGF withdrawal. C: Primary sympa-
thetic neurons were electroporated to produce
GFP alone (GFP) or GFP and Myc-tagged JunB
(JunB) and treated with NGF for 3 days. Shown
is the percentage of GFP-positive cells with
apoptotic nuclei after continued NGF treat-
ment (open bars) or 48 hr after NGF withdrawal
(hatched bars). D: Immunoblot of PC12 cells
transfected to produce the indicated c-RET pro-
teins or Myc-tagged PKC-λ and grown in the
absence of NGF. Error bars = 1 standard devi-
ation.influences EglN3-induced apoptosis by cotransfecting undif-
ferentiated PC12 cells with plasmids encoding HA-EglN3 and
GFP-histone in the presence or absence of pharmacological
SDH inhibitors. Three different inhibitors, malonic acid (MA),
3-nitroproprionic acid (3-NPA), and thenoyl trifluoroacetone
(TTFA), decreased EglN3-induced apoptosis (Figures 6C and
6D). Notably, HIF-α protein levels were not increased by these
agents, in contrast to PC12 cells treated with the hypoxia-
mimetic cobalt chloride, which further argues that EglN3-
induced neuronal apoptosis is HIF-α independent (Figure 6E).
Coadministration of the antioxidant ascorbic failed to mitigate
the effects of the SDH inhibitors on EglN3-induced apoptosis
despite blocking ROS induction (Figures 6B and 6F), suggest-
ing that a non-ROS mechanism such as succinate accumula-
tion attenuates EglN3-induced apoptosis when SDH activity
is impaired.
To assess the role of SDH in neuronal apoptosis in a more160physiological context, we next transfected PC12 cells with the
GFP-histone plasmid along with siRNAs prior to NGF treatment
and withdrawal. Two different SDHD siRNAs, but not various
control siRNAs, dramatically decreased apoptosis after NGF
withdrawal (Figure 6G and Figures S8 and S9). Notably, apo-
ptosis was partially restored in this setting by the addition of
2-OG to the media (Figure 6G). The SDH inhibitors (MA or
3-NPA) also diminished apoptosis in this setting (Figure S10).
Taken together, these findings suggest that inactivation of
SDH, by promoting the accumulation of succinate, impairs
EglN3-induced apoptosis and promotes survival when NGF
levels become limiting.
c-Jun acts upstream of SM-20/EglN3
in the NGF signaling pathway
We next asked if SM-20/EglN3 and c-Jun function in the same
pathway. Apoptosis induced by overexpression of EglN3 inCANCER CELL : AUGUST 2005
A R T I C L EFigure 5. EglN3 is sufficient and necessary for induction of apoptosis by NGF withdrawal
A: Anti-SM-20/EglN3 immunoblot analysis of PC12 cells treated as in Figure 3A. B and D: Representative fluorescent photomicrographs (B) and anti-HA
immunoblot analysis (D) of PC12 cells transfected to produce GFP-histone and the indicated HA-EglN species. White arrows in A indicate apoptotic nuclei.
C: Percentage of GFP-positive nuclei with apoptotic changes after transfection with 0.5 or 1.0 g of the indicated plasmids. E and F: Representative
fluorescent photomicrographs of PC12 cells transfected with the indicated siRNAs and a plasmid encoding GFP-histone followed by treatment with NGF
for 10 days (+NGF), which was then withdrawn for 24 hr (−NGF). White arrows indicate apoptotic nuclei, which were quantitated in E as percentage of
GFP-positive nuclei. G and H: Representative fluorescent photomicrographs (G) of PC12 cells transfected to produce GFP-histone and treated with NGF
for 5 days (+NGF), which was then withdrawn for 24 hr (−NGF). Where indicated, cells were exposed to 100 M CoCl2 or 1% hypoxia during NGF withdrawal.
White arrows indicate apoptotic nuclei, which were quantitated in H as percentage of GFP-positive nuclei. Error bars = 1 standard deviation.PC12 cells, in contrast to that induced by NGF withdrawal, was
not reduced by coexpression of the c-Jun antagonist JunB
(Figure 7A). In a reciprocal set of experiments, PC12 cells were
cotransfected with plasmids encoding an activated, stabilized
version of c-Jun (c-Jun) and GFP-histone. Inclusion of SM-
20 siRNAs, but not control siRNAs, in the transfection mix dra-
matically reduced c-Jun-dependent apoptosis, arguing that
SM-20/EglN3 acts downstream of or parallel to c-Jun (Figure
7B). In support of the former possibility, wild-type, but not mu-
tant, c-Jun activated a luciferase reporter plasmid containing
the SM-20 promoter in cotransfection assays (Figure 7C), and
SM-20 levels increased in PC12 cells infected with an adenovi-
rus encoding c-Jun (Figure 7D).
EglN3 is induced by NGF withdrawal but also by HIF (Apreli-
kova et al., 2004; Cioffi et al., 2003; del Peso et al., 2003; Marx-
sen et al., 2004). Therefore, pVHL has opposing effects onCANCER CELL : AUGUST 2005EglN3, and the balance of those effects might dictate the risk
of developing pheochromocytoma. In support of this, we de-
tected high basal EglN3 mRNA and protein levels in 786-O
cells producing type 1 pVHL mutants (as well as in 786-O cells
stably transfected with an empty vector), which are associated
with a low risk of pheochromocytoma, and low EglN3 levels in
786-O cells producing type 2 pVHL mutants, which are associ-
ated with a high risk of pheochromocytoma (Figures 7E and
7F). We do not currently understand why EglN3 levels are low
in cells producing type 2A and type 2B pVHL mutants, how-
ever, since the HIF and JunB levels in these cells are compara-
ble to those observed in cells producing type 1 pVHL mutants
(Figure 7E and Figure S11). Gene expression profiling indicates
that a subset of HIF target genes, including EglN3, are inhibited
by type 2 pVHL mutants despite increased HIF levels (data not
shown). This might reflect a residual physical interaction be-161
A R T I C L EFigure 6. SDH activity is required for EglN3-induced apoptosis
A: Binding of 35S-labeled pVHL to biotinylated HIF-1α peptide after preincubation with unprogrammed reticulocyte lysate (RRL), EglN3 in vitro translate
(EglN3 IVT), or EglN3 IVT with the indicated concentrations of succinate and 2-oxoglutarate. 35S-pVHL was loaded directly in lane 1 as a control.
B: FACS profiles of PC12 cells stained with the ROS-sensitive dye CM-H2DCFDA after treatment with the indicated SDH inhibitors or the ROS-inducing agent
rotenone (Ro; 20 M) in the presence or absence of the ROS scavenger ascorbic acid (AA; 100 M). C, control.
C and D: Representative fluorescent photomicrographs of PC12 cells (C) transfected to produce GFP-histone alone (GFP-His) or GFP-histone and EglN3
(EglN3). The SDH inhibitors 3-NPA (300 M), MA (300 M), or TTFA (200 M) were added where indicated. White arrows indicate apoptotic nuclei, which
were quantitated in D as percentage of GFP-positive nuclei.
E: Immunoblot analysis of PC12 cells treated with the indicated chemicals or vehicle (C).
F: Percentage of GFP-positive PC12 nuclei undergoing apoptosis after transfection to produce GFP-histone alone (GFP-His) or GFP-histone and EglN3
(EglN3) in the presence or absence of SDH inhibitors. One hundred micromolar AA was also present where indicated.
G: Percentage of GFP-positive PC12 nuclei undergoing apoptosis after transfection with the indicated siRNAs and a plasmid encoding GFP-histone
followed by treatment with NGF for 5 days (+NGF), which was then withdrawn for 24 hr (−NGF). Where indicated, 0.5 mM 2-oxoglutarate was added to
the media 24 hr before NGF withdrawal.
Error bars = 1 standard deviation.tween pVHL and HIF that affects HIF function rather than HIF
stability. Alternatively, it might reflect a pVHL activity directed
against a protein that cooperates with HIF to activate tran-
scription.162Discussion
We discovered that inactivation of pVHL leads to increased
levels of JunB and that induction of JunB in this setting reflectsCANCER CELL : AUGUST 2005
A R T I C L EFigure 7. EglN3 activity is required for Jun-
induced apoptosis
A: Percentage of GFP-positive PC12 nuclei un-
dergoing apoptosis transfected to produce GFP-
histone alone (GFP-His) or GFP-histone and EglN3
(EglN3) with or without Myc-tagged JunB.
B: Percentage of GFP-positive PC12 nuclei un-
dergoing apoptosis transfected with plasmids
encoding GFP-histone alone (GFP-His) or GFP-
histone and activated c-Jun (c-Jun) along with
the indicated siRNAs.
C: Normalized luciferase values of PC12 cells
transfected with reporter plasmid containing
firefly luciferase under the control of SM-20 pro-
moter and plasmid encoding wild-type or mu-
tant (DNA binding-defective) c-Jun.
D: Immunoblot analysis of PC12 cells infected
with adenovirus encoding c-Jun or β-galactosi-
dase at indicated multiplicity of infection (MOI).
E and F: Immunoblot (E) and semiquantitative
RT-PCR analysis (F) of 786-O cells stably trans-
fected to produce the indicated pVHL species.
Error bars = 1 standard deviation.both increased aPKC activity and increased HIF levels. Every
disease-associated pVHL mutant tested so far, including famil-
ial pheochromocytoma pVHL mutants that retain the ability to
degrade HIF, fails to downregulate JunB. JunB can antagonize
c-Jun in certain settings. Increased JunB levels attenuate the
induction of apoptosis in pheochromocytoma cells after NGF
withdrawal, which is mediated by c-Jun. Another protein sus-
pected of playing a role in apoptosis following NGF withdrawal
is EglN3. We found that EglN3 is both necessary and sufficient
for the induction of apoptosis after NGF withdrawal and is
unique among the three EglN family members in this regard.
Moreover, EglN3 appears to act downstream of c-Jun and is
sensitive to changes in SDH activity.
Our findings solidify the role of pVHL in the regulation of
aPKC (Okuda et al., 1999, 2001; Pal et al., 1997) and place this
regulation in a physiological context. Earlier studies showed
that aPKC is activated by NGF (Vandenplas et al., 2002;
Wooten et al., 2001), which regulates both c-Jun and JunB.
pVHL antagonizes activated aPKC and thereby attenuates
NGF signaling.
Our findings provide mechanistic links between SDH muta-CANCER CELL : AUGUST 2005tions, EglN3 activity, and escape from neuronal apoptosis. Inhi-
bition of EglN3 after SDH inactivation appears to be due to the
accumulation of succinate, which can be transported to the
cytosol by the dicarboxylate carrier located on the inner mito-
chondrial membrane. Additional studies will be required to
determine the ratios of succinate/2-OG achieved in specific
subcellular compartments when SDH activity is impaired. This
information, along with differences in subcellular localization
(Metzen et al., 2003) and sensitivity to 2-OG analogs (Hirsila et
al., 2003) among the EglN paralogs, might explain our failure to
detect accumulation of the EglN1 target HIF-α following SDH
inactivation in PC12 cells as well as in many other cell types
(data not shown). This, as well as other lines of evidence pre-
sented here, strongly suggests that HIF is not the relevant tar-
get of SDH and EglN3 with respect to neuronal apoptosis.
Nonetheless, our data do not preclude the possibility that SDH
inactivation also affects EglN1 and HIF, especially after pro-
longed SDH inactivation or in susceptible cell types. For exam-
ple, increased HIF activity has been observed in 293T human
embryonic kidney cells treated with SDH inhibitors (Selak et
al., 2005), in pheochromocytomas linked to SDH mutations (Gi-163
A R T I C L Emenez-Roqueplo et al., 2001), and in papillary renal cancers
linked to mutations in fumarate hydratase (FH), which acts
downstream of SDH (Isaacs et al., 2005).
Germline mutations in either NF1, c-RET, SDH, or VHL cause
familial pheochromocytoma and the related tumor, paragangli-
Aoma (Bryant et al., 2003; Maher and Eng, 2002). Based on our
studies, we propose that deregulation of NGF signaling is the
relevant unifying feature of these mutations (Figure 8). NF1 in-
hibits downstream signaling by NGF receptor TrkA. Accord-
ingly, loss of NF1 promotes NGF-independent survival of em-
bryonic peripheral neurons (Vogel et al., 1995). c-RET is the
receptor for GDNF (glial cell line-derived neurotrophic factor)
and can crosstalk with the NGF receptor TrkA (Dechant, 2002;
Peterson and Bogenmann, 2004; Tsui-Pierchala et al., 2002).
We found that activation of c-RET, like loss of pVHL, leads to
the induction of JunB and attenuates apoptosis after NGF
withdrawal. Finally, SDH inactivation blunts neuronal apoptosis
through its effects on EglN3. We propose that mutations in
these genes cause pheochromocytoma because certain neu-
ronal precursor cells with the capability of forming pheochro-
mocytomas are not properly culled during development. Muta-
tion of these genes would no longer be detrimental, however,
once this developmental window had passed. This model
would explain why somatic NF1, c-RET, SDH, and VHL are ex-
tremely rare in nonhereditary pheochromocytomas (Maher and
Eng, 2002) and are mutually exclusive. At the same time,
w25% of seemingly sporadic pheochromocytomas are due to
previously unsuspected germline mutations in one of these
four genes (Neumann et al., 2002).
Abnormal NGF signaling has been linked to other cancers,
including the pediatric tumors neuroblastoma and medullo-
blastoma (Katsetos et al., 2003; Nakagawara, 2001). It is tempt-
ing to speculate that alterations in developmental apoptosis
play a role in these tumors also, especially in light of the spon-
taneous regressions that sometimes occur in neuroblastoma
patients who present within the first year of life. Neuro-
blastoma, like pheochromocytoma, is derived from neural crest
progenitor cells that give rise to the sympathetic nervous sys-
tem, adrenal medulla, and adrenergic and cholinergic neuro-
blasts along the sympathetic chain and cranial ganglia. Our
findings might also be relevant to the earlier observation that
pVHL can transform neuroblastoma cells into functional neu-
ron-like cells (Murata et al., 2002).
In summary, we propose that germline NF1, c-RET, SDH,
and VHL mutations allow sympathetic neuronal progenitors to
escape from developmental apoptosis and thereby set theFigure 8. Model linking familial pheochromocytoma genes to apoptosis
after NGF withdrawal164stage for their neoplastic transformation. In contrast, somatic
mutations in these genes in the adult would not predispose to
pheochromocytoma, in keeping with molecular epidemiologi-
cal data. It is possible that escape from developmental apopto-
sis plays a role in pediatric cancers and other forms of heredi-
tary cancer as well.
Experimental procedures
Cell lines
The 786-O and A498 renal carcinoma cell line derivatives are described
elsewhere (Kondo et al., 2003; Lonergan et al., 1998) and were maintained
in Dulbecco’s modified Eagle’s medium (DMEM) containing 10% fetal clone
(Hyclone) and, where appropriate, G418 and/or puromycin, in the presence
of 10% CO2 at 37°C. Undifferentiated PC12 cells were maintained in DMEM
containing 10% fetal bovine serum (Hyclone) and 5% horse serum (Sigma)
in 37°C, 10% CO2 incubator.
Plasmids
The human JunB open reading frame cDNA in a Gateway entry plasmid (a
gift of Marc Vidal) was transferred to the Gateway expression vector
pDEST47 (Invitrogen) by recombination cloning to make pDEST47-JunB.
The JunB cDNA was PCR amplified with primer A (5#-GGGGACAAGTTTGT
CAAAAAAGCAGGCTATGTGCACTAAAATGGAACAGCCCT-3#) and primer
B (5#-GGGGACCACTTTGTACAAGAAAGCTGGGTCCTAGCGCGCGATGCG
CTCCAGCTT-3#) to make the JunBbZip cDNA, which was transferred to
pDEST47 by sequential BP and LR recombination reactions according to
the manufacturer’s instructions (Invitrogen). The human c-RET cDNA, en-
coding the short 1072 residue c-RET isoform, in a Gateway entry plasmid
(a gift of Marc Vidal), was similarly transferred to pDEST47 (Invitrogen) by
recombination cloning to make pDEST47-c-RET. The c-RET cDNA was
PCR amplified with primer C (5#-CCACTGTGCGACGAGCTGCGCCGCA
CGGTGATCGCAGCC-3#) and primer D (5#-GGCTGCGATCACCGTGCGG
CGCAGCTCGTCGCACAGTGG-3#) to make the constitutively active C634R
c-RET mutant, which was also transferred to pDEST47.
The pVHL expression plasmids have been described before (Hoffman et
al., 2001).
The expression plasmids for HA-EglN1 (Ivan et al., 2002) and HA-HIF-
2α P405A;P531A (Kondo et al., 2003) were described previously, and the
plasmids for HA-EglN2, HA-EglN3, and HA-HIF-1α P402A;P564A were
made analogously. HA-EglN3 H196A was made using a site-directed muta-
genesis kit (GeneEditor; Promega). The pcDNA-Myc-JunB was made by
PCR amplification of IMAGE-clone MGC 10557 with primers that intro-
duced a 5# BamH1 site and 3# EcoR1 site followed by ligation into 5x-myc-
pcDNA3. The plasmid encoding human c-Jun, which harbors mutations
analogous to the chicken v-Jun mutations, was described before (Wei et
al., 2005). To make the c-Jun leucine zipper mutant, a c-Jun cDNA corre-
sponding to residues 1–255 was amplified by PCR with primers that intro-
duced a 5# BamHI site and 3# EcoRI site and ligated into 5x-myc-pcDNA3.
All cDNAs were sequence verified.
EMSA
Synthetic oligonucleotides were end labeled with [γ32P]-ATP and T4 DNA
Kinase (New England Biolabs) according to the manufacturer’s instructions
and annealed in vitro for use in EMSA containing 5 g of nuclear extract (9
g for supershift assays), prepared using a Nuclear Extract Kit (Active Mo-
tif), in a final volume of 20 l in the presence of 10 mM Tris-HCl (pH 7.5),
50 mM NaCl, 1 mM EDTA, 10% glycerol, 1 mM DTT, and 2 g of poly
(dl-dC). The clusterin promoter-derived EMSA probe sequences (sense
strands) were as follows: wild-type, 5#-TTCTTTGGGCGTGAGTCATGCA-3#;
AP-1, 5#-TTCTTTGGGCGTGAGGCATGCA-3#; Sp1, 5#-TTCTTTGTTCGT
GAGTCATGCA-3#. Canonical binding site probe sequences (sense) were as
follows: Sp1, 5#-ATTCGATCGGGGCGGGGCGAGC-3#; and AP-1, 5#-CGC
TTGATGAGTCAGCCGGAA-3#. Competitor unlabeled probes were an-
nealed in vitro and used at 50-fold molar excess of labeled probe. Su-
pershift assays were performed with polyclonal anti-JunB Nushift Antibody
(Active Motif) and Nushift Kit (Active Motif) according to the manufacturer’s
instructions. Differential supershifts were not observed with antisera against
c-Fos or c-Jun (data not shown).CANCER CELL : AUGUST 2005
A R T I C L EImmunoblot analysis
Twenty micrograms of nuclear extract per lane, prepared using a NE-PER
extraction kit (Pierce) and measured by the Bradford assay, was resolved
on 10% or 12% SDS-PAGE gels and transferred to nitrocellulose membrane
(Bio-Rad) to detect endogenous JunB and HIF-2α. After blocking in TBS
with 5% nonfat milk, the membranes were probed with anti-JunB monoclo-
nal antibody (C-11; Santa Cruz Biotechnology) or anti-HIF-2α rabbit poly-
clonal antibody (NB100-122; Novus Biologicals). Bound protein was de-
tected with horseradish peroxidase (HRP)-conjugated secondary antibodies
and an enhanced chemiluminescence kit (Pierce).
HA-EglN1, HA-EglN2, HA-EglN3, HA-H196A, and HA-HIF-2α were de-
tected in whole-cell extracts using polyclonal α-HA (Y-11; Santa Cruz). HA-
HIF-1α was detected using monoclonal anti-HIF-1α (Transduction Lab). The
antibody against EglN3/SM-20 was a gift of Peter Ratcliffe and was de-
scribed previously (Appelhoff et al., 2004). The antibody against rodent HIF-
1α, which also recognizes HIF-2α (data not shown), was a gift of Jacques
Pousegeur and was described in Berra et al. (2003).
siRNA
Short interfering RNA (siRNA) oligonucleotides were purchased from Dhar-
macon. Sense strand sequences were as follows: rVHL, 5#-AAUGUUGA
UGGACAGCCUAUU-3#; hVHL #7, 5#-AAUGUUGACGGACAGCCUAUU-3#;
GL3, 5#-CUUACGCUGAGUACUUCGAUU-3#; scramble, 5#-AACAGUCGCG
UUUGCGACUGG-3#; SM-20 #1, 5#-CAGGUUAUGUUCGUCAUGUdTdT-3#;
SM-20 #2, 5#-UUCUCCUGGUCAGACCGCAdTdT-3#; SDHD #1, 5#-GUU
GCCAUGCUGUGGAAGCdTdT-3#; SDHD #2, 5#-UUGGACAAGUGGUUA
CUGAdTdT-3#.
In vitro kinase assays
In vitro kinase assays were performed as described elsewhere (Standaert
et al., 2004) using a rabbit polyclonal antibody that recognizes the C termini
of both PKC-λ and PKC-ζ (Santa Cruz Biotechnologies). Immunoprecipi-
tates were incubated for 8 min at 30°C in 100 l buffer containing 50 mM
Tris/HCl (pH 7.5), 100 M Na3VO4, 100 M Na4 P2O7, 1 mM NaF, 100 M
PMSF, 4 g phosphatidylserine (Sigma), 50 M [γ-32P]ATP (NEN Life Sci-
ence Products), 5 mM MgCl2, and as substrate, 40 M serine analog of the
PKC- pseudosubstrate (BioSource). After incubation, 32P-labeled sub-
strate was trapped on P-81 filter papers and counted.
Apoptosis assays
Undifferentiated PC12 cells were plated onto collagen-coated 6-well plates
1 day before transfection with Lipofectamine 2000 (Invitrogen) according to
the manufacturer’s instructions. Transfection mixes contained 500 ng of a
plasmid encoding GFP-histone (a gift of Geoffrey Wahl), 1 g of the cDNA
expression plasmid of interest, and where indicated, 100 nM of siRNA.
Forty-eight hours later, the cells were trypsinized, transferred to collagen-
coated p100 dishes, and grown in DMEM supplemented with 1% horse
serum and NGF (50 ng/ml) for 5–7 days. For NGF withdrawal, cells were
washed once with serum-free medium followed by incubation in NGF-free
medium containing a neutralizing antibody against the 2.5S and 7S forms
of NGF (Accurate Chemical) at a 1:400 dilution. Control cells were washed
once in NGF-free medium and then returned to NGF-containing medium.
Nuclei that were condensed or fragmented were scored as apoptotic. Ap-
proximately 400 cells were scored for each set of conditions, and all assays
were performed in triplicate.
Isolation of primary sympathetic neurons
Sympathetic neurons were isolated from the superior cervical ganglia (SCG)
as previously described (Palmada et al., 2002). Briefly, SCG from Sprague-
Dawley rats were isolated at postnatal day 4, and sympathetic neurons were
dissociated with 0.25% trypsin and 0.3% collagenase for 30 min at 37°C.
After dissociation, the neurons were electroporated with pmax-GFP alone
(Amaxa) or pmax-GFP along with JunB expression plasmid according to
the manufacturer’s instructions (Amaxa Rat Neuron Nucleofector kit). The
neurons were then cultured on poly-L-ornithine and laminin-coated 4-well
slides (Nalge Nunc International) in Ultraculture medium (BioWhittaker) sup-
plemented with 3% fetal calf serum (Gibco), 2 mM L-glutamine (Gibco),
and 20 ng/ml NGF (Harlan). The neurons were maintained for 3 days in the
presence of NGF and then washed twice in Ultraculture medium lacking
NGF and once with Ultraculture containing an antibody to NGF at 0.1 g/CANCER CELL : AUGUST 2005ml (Chemicon International), and returned to NGF-free media. The cells
were fixed in paraformaldehyde 48 hr later, and the number of GFP-positive
neurons with apoptotic nuclei, identified by DAPI staining (Vector Labs),
were counted. At least 75 neurons were evaluated for each condition.
Hydroxylation assays
Hydroxylation assays were performed essentially as described before (Ivan
et al., 2002).
ROS analysis
PC12 cells were incubated for 1 hr with 5 M CM-H2DCFDA (Molecular
Probes), harvested, resuspended at 106 cells/ml in PBS supplemented with
7% FBS, and analyzed by FACS.
Luciferase assays
The HRE reporter was described in Kondo et al. (2002). The SM-20 pro-
moter reporter was described in Menzies et al. (2004). Luciferase assays
were performed in triplicate using a luciferase dual reporter assay system
(Promega).
Adenovirus
The adenovirus encoding c-Jun was described earlier (Yu et al., 2001) and
was a gift of Dr. Jason X.-J. Yuan.
Semiquantitative RT-PCR
Total RNAs were extracted with RNeasy Mini Kit (Qiagen). cDNA synthesis
and PCR amplification were performed with Superscript One-Step RT-PCR
(Invitrogen) using 1 g total RNA. EglN3 cDNA was amplified with sense
primer (5#-GCGTCTCCAAGCGACA-3#) and antisense primer (5#-GTCTTC
AGTGAGGGCAGA-3#) for 32 cycles. As a control, GAPDH cDNA was also
amplified with sense primer (5#-CTACACTGAGCACCAGGTGGTCTC-3#)
and antisense primer (5#-GATGGATACATGACAAGGTGCGGC-3#). Ten mi-
croliter aliquots of the PCR reaction (50 l) were separated on a 2% aga-
rose gel.
Supplemental data
The Supplemental Data include eleven supplemental figures and can be
found with this article online at http://www.cancercell.org/cgi/content/full/8/
2/155/DC1/.
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